[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)
Determine if a study site for this clinical trial is near you. Contact the study to apply.
Find a Study SiteCall center
Email address
Condition
Treatment type
Investigational product
Phase
Sponsor
ClinicalTrials.gov identifier
Study number
Get answers to your questions about clinical trials.
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-453 in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in disease activity will be assessed. ABBV-453 is an investigational drug being developed for the treatment of R/R MM. This study will include a dose escalation phase to determine the best dose of ABBV-453. Approximately 21 adult participants with R/R MM will be enrolled in the study in approximately 12 sites worldwide. Participants will receive oral ABBV-453 tablets once daily (QD) in 28-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.
You may be eligible to participate in the study if you meet the following criteria:
For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
Determine if a study site for this clinical trial is near you. Contact the study to apply.
Find a Study Site